Cargando…

Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development

OBJECTIVES: To assess messenger RNA (mRNA) expression of POU2AF1 and Spi-B and their potential regulatory microRNAs (miRNAs) in natalizumab-treated patients with multiple sclerosis and in therapy-associated progressive multifocal leukoencephalopathy (PML). METHODS: Expression of POU2AF1/Spi-B was an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meira, Maria, Sievers, Claudia, Hoffmann, Francine, Haghikia, Aiden, Rasenack, Maria, Décard, Bernhard F., Kuhle, Jens, Derfuss, Tobias, Kappos, Ludwig, Lindberg, Raija L.P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821666/ https://www.ncbi.nlm.nih.gov/pubmed/27088119 http://dx.doi.org/10.1212/NXI.0000000000000223

Ejemplares similares

Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4(+) T Cells of Patients with Relapsing-Remitting Multiple Sclerosis
por: Meira, Maria, et al.
Publicado: (2014)

PARP-1 deregulation in multiple sclerosis
por: Meira, Maria, et al.
Publicado: (2019)

Metabolic profiles by (1)H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML)
por: Schneider, Ruth, et al.
Publicado: (2017)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Alterations of the miR-126-3p/POU2AF1/Spi-B Axis and JCPyV Reactivation in Multiple Sclerosis Patients Receiving Natalizumab
por: Mancuso, Roberta, et al.
Publicado: (2022)

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
por: Fischer-Barnicol, Bettina, et al.
Publicado: (2020)

Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS
por: Zimmermann, Maria, et al.
Publicado: (2015)

Treatment of natalizumab‐associated PML with filgrastim
por: Stefoski, Dusan, et al.
Publicado: (2019)

Efficacy and Safety of Fingolimod in an Unselected Patient Population
por: Rasenack, Maria, et al.
Publicado: (2016)

Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc
por: Bsteh, Gabriel, et al.
Publicado: (2017)

Improving risk‐stratification of natalizumab‐associated PML
por: Tugemann, Bastian, et al.
Publicado: (2021)

Hepatitis E virus infections in patients with MS on oral disease-modifying treatment
por: Diebold, Martin, et al.
Publicado: (2019)

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab
por: Antoniol, Caroline, et al.
Publicado: (2015)

Concomitant granule cell neuronopathy in patients with natalizumab-associated PML
por: Wijburg, Martijn T., et al.
Publicado: (2016)

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
por: Killestein, J., et al.
Publicado: (2014)

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
por: Dong-Si, Tuan, et al.
Publicado: (2014)

Pathologic Findings of Chronic PML-IRIS in a Patient with Prolonged PML Survival Following Natalizumab Treatment
por: Himedan, Mai, et al.
Publicado: (2017)

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study
por: Malucchi, Simona, et al.
Publicado: (2016)

Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities
por: Honce, Justin M., et al.
Publicado: (2015)

Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS
por: Hodecker, Sibylle C., et al.
Publicado: (2017)

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome
por: Maillart, Elisabeth, et al.
Publicado: (2017)

Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis
por: Diebold, Martin, et al.
Publicado: (2022)

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab
por: Toboso, Inmaculada, et al.
Publicado: (2020)

Sequencing and Analysis of JC Virus DNA From Natalizumab-Treated PML Patients
por: Reid, Carl E., et al.
Publicado: (2011)

Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus
por: Werner, Milton H., et al.
Publicado: (2016)

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
por: Ryerson, Lana Zhovtis, et al.
Publicado: (2019)

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Maraviroc in PML-IRIS: A separate ball game under HIV infection and natalizumab?
por: Steiner, Israel, et al.
Publicado: (2017)

α4-integrin receptor desaturation and disease activity return after natalizumab cessation
por: Derfuss, Tobias, et al.
Publicado: (2017)

A link between long-term natalizumab dosing in MS and PML: Putting the puzzle together
por: Major, Eugene O., et al.
Publicado: (2016)

7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case study
por: Sinnecker, Tim, et al.
Publicado: (2015)

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy
por: Rust, Heiko, et al.
Publicado: (2016)

Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis
por: Cerdá-Fuertes, Nuria, et al.
Publicado: (2023)

POU2AF1 promotes MSCs adipogenesis by inhibiting HDAC1 expression
por: Wang, Yaqing, et al.
Publicado: (2021)

Ultrasonographic reference values for peripheral nerves and nerve roots in the normal population of children and adolescents: study protocol for an observational-prospective trial
por: Rasenack, Maria, et al.
Publicado: (2016)

Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype
por: Pröbstel, Anne-Katrin, et al.
Publicado: (2015)

CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients
por: Lieberman, Linda A., et al.
Publicado: (2016)

Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML
por: Alleg, Manel, et al.
Publicado: (2020)

Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment
por: Muñoz-Vendrell, Albert, et al.
Publicado: (2023)

POU class 2 homeobox associating factor 1 (POU2AF1) participates in abdominal aortic aneurysm enlargement based on integrated bioinformatics analysis
por: Meng, Jinze, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5e777m0fk6am17ng00lsl1c663